The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Active targeting schemes for nanoparticle systems in cancer therapeutics
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Nanoparticles in Medicine: Therapeutic Applications and Developments
Zhang, L., Gu, F., Chan, J., Wang, A., Langer, R., & Farokhzad, O. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100400 · Cited by 2,657
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
PEGylation, successful approach to drug delivery
Veronese, F. M., & Pasut, G. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03575-0 · Cited by 2,339
Nanoparticle and targeted systems for cancer therapy
Brannon-Peppas, L., & Blanchette, J. O. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.02.014 · Cited by 2,334
Self-citationKam, N. W. S., O'Connell, M., Wisdom, J. A., & Dai, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502680102 · Cited by 2,307
Plate, K. H., Breier, G., Weich, H. A., & Risau, W. (1992) · Nature · doi:10.1038/359845a0 · Cited by 2,275
Nicholson, R. I., Gee, J. M. W., & Harper, M. E. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00231-3 · Cited by 2,143
Gref, R., Lück, M., Quellec, P., Marchand, M., Dellacherie, E., Harnisch, S., Blunk, T., & Müller, R. H. (2000) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/s0927-7765(99)00156-3 · Cited by 1,723
Osborn, L., Hession, C., Tizard, R., Vassallo, C., Luhowskyj, S., Chi-Rosso, G., & Lobb, R. (1989) · Cell · doi:10.1016/0092-8674(89)90775-7 · Cited by 1,689
Isolation of a tumor factor responsible for angiogenesis
Folkman, J., Merler, E., Abernathy, C., & Williams, G. (1971) · The Journal of Experimental Medicine · doi:10.1084/jem.133.2.275 · Cited by 1,663
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601755103 · Cited by 1,663
PEGylated nanoparticles for biological and pharmaceutical applications
Otsuka, H., Nagasaki, Y., & Kataoka, K. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00226-0 · Cited by 1,588
(1997) · PubMed · Cited by 1,541
Targeted drug delivery via the folate receptor
Sudimack, J., & Lee, R. J. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(99)00062-9 · Cited by 1,474
Formulation of functionalized PLGA-PEG Nanoparticles for in vivo targeted drug delivery
Cheng, J., Teply, B. A., Sherifi, I., Sung, J., Luther, G., Gu, F. X., Levy-Nissenbaum, E., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.09.047 · Cited by 1,273
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
Mendelsohn, J., & Baselga, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.504 · Cited by 1,255
Kirpotin, D. B., Drummond, D. C., Shao, Y., Shalaby, M. R., Hong, K., Nielsen, U. B., Marks, J. D., Benz, C. C., & Park, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4199 · Cited by 1,125
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
Ferrara, N., Hillan, K. J., & Novotny, W. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.132 · Cited by 977
Kukowska-Latallo, J. F., Candido, K. A., Cao, Z., Nigavekar, S. S., Majoros, I. J., Thomas, T. P., Balogh, L. P., Khan, M. K., & Baker, J. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3921 · Cited by 912
Nanoparticle-Aptamer Bioconjugates
Farokhzad, O. C., Jon, S., Khademhosseini, A., Tran, T.-N. T., LaVan, D. A., & Langer, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2550 · Cited by 897
Tumor Regression by Targeted Gene Delivery to the Neovasculature
Hood, J. D., Bednarski, M., Frausto, R., Guccione, S., Reisfeld, R. A., Xiang, R., & Cheresh, D. A. (2002) · Science · doi:10.1126/science.1070200 · Cited by 858
Nanoparticles for drug delivery in cancer treatment
Haley, B., & Frenkel, E. (2008) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.03.015 · Cited by 791
Regulation of angiogenesis via vascular endothelial growth factor receptors.
Veikkola, T., Karkkainen, M. J., Claesson, L., & Alitalo, K. K. (2000) · PubMed · Cited by 749
Specialization of tumour vasculature
Ruoslahti, E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc724 · Cited by 722
Elnakat, H. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.01.001 · Cited by 649
Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Manseau, E. J., Senger, D. R., & Dvorak, H. F. (1993) · PubMed · Cited by 635
Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D., & Weiner, L. M. (2001) · PubMed · Cited by 629
An Aptamer–Doxorubicin Physical Conjugate as a Novel Targeted Drug‐Delivery Platform
Bagalkot, V., Farokhzad, O. C., Langer, R., & Jon, S. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200602251 · Cited by 613
Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro
Lee, R. J., & Low, P. S. (1995) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(94)00235-h · Cited by 574
Hu-Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E., & Triche, T. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0565 · Cited by 567
Hamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602479 · Cited by 565
Functionalized micellar systems for cancer targeted drug delivery
Sutton, D., Nasongkla, N., Blanco, E., & Gao, J. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9223-y · Cited by 557
PEGylated antibodies and antibody fragments for improved therapy: a review
Chapman, A. P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00026-1 · Cited by 556
Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis.
Leamon, C. P., & Low, P. S. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.13.5572 · Cited by 554
A PEGylated dendritic nanoparticulate carrier of fluorouracil
Bhadra, D., Bhadra, S., Jain, S., & Jain, N. K. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00132-7 · Cited by 544
Transferrin receptors in human tissues: their distribution and possible clinical relevance.
Gatter, K. C., Brown, G., Trowbridge, I. S., Woolston, R. E., & Mason, D. Y. (1983) · Journal of Clinical Pathology · doi:10.1136/jcp.36.5.539 · Cited by 531
Increased exposure of anionic phospholipids on the surface of tumor blood vessels.
Ran, S., Downes, A., & Thorpe, P. E. (2002) · PubMed · Cited by 471
Fiedler, W., Graeven, U., Ergün, S., Verago, S., Kilic, N., Stockschläder, M., & Hossfeld, D. K. (1997) · Blood · doi:10.1182/blood.v89.6.1870 · Cited by 437
cRGD‐Functionalized Polymer Micelles for Targeted Doxorubicin Delivery
Nasongkla, N., Shuai, X., Ai, H., Weinberg, B. D., Pink, J., Boothman, D. A., & Gao, J. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200460800 · Cited by 434
Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice.
Thurston, G., McLean, J. W., Rizen, M., Baluk, P., Haskell, A., Murphy, T. J., Hanahan, D., & McDonald, D. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci965 · Cited by 423
A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth
Niethammer, A. G., Xiang, R., Becker, J. C., Wodrich, H., Pertl, U., Karsten, G., Eliceiri, B. P., & Reisfeld, R. A. (2002) · Nature Medicine · doi:10.1038/nm1202-794 · Cited by 400
Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.
Pinto, J. T., Suffoletto, B. P., Berzin, T. M., Qiao, C. H., Lin, S., Tong, W. P., May, F., Mukherjee, B., & Heston, W. D. W. (1996) · PubMed · Cited by 389
Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment
Grunwald, V., & Hidalgo, M. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.12.851 · Cited by 383
Heidel, J. D., Yu, Z., Liu, J. Y.-C., Rele, S. M., Liang, Y., Zeidan, R. K., Kornbrust, D. J., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701458104 · Cited by 382
Jain, R. K., Safabakhsh, N., Sckell, A., Chen, Y., Jiang, P., Benjamin, L., Yuan, F., & Keshet, E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10820 · Cited by 374
Therapeutic antibody fragments with prolonged in vivo half-lives
Chapman, A. P., Antoniw, P., Spitali, M., West, S., Stephens, S., & King, D. J. (1999) · Nature Biotechnology · doi:10.1038/11717 · Cited by 350
Transferrin-Containing, Cyclodextrin Polymer-Based Particles for Tumor-Targeted Gene Delivery
Bellocq, N. C., Pun, S. H., Jensen, G. S., & Davis, M. E. (2003) · Bioconjugate Chemistry · doi:10.1021/bc034125f · Cited by 350
Fibronectin and Its Integrin Receptors in Cancer
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60772-1 · Cited by 330
Fighting Cancer by Attacking its Blood Supply
Folkman, J. (1996) · Scientific American · doi:10.1038/scientificamerican0996-150 · Cited by 328
Radinsky, R., Risin, S. A., Fan, D., Dong, Z., Bielenberg, D. R., Bucana, C. D., & Fidler, I. J. (1995) · PubMed · Cited by 321
Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels
Krasnici, S., Werner, A., Eichhorn, M. E., Schmitt‐Sody, M., Pahernik, S. A., Sauer, B., Schulze, B., Teifel, M., Michaelis, U., Naujoks, K., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.11108 · Cited by 313
Folate receptor-targeted drugs for cancer and inflammatory diseases
Low, P. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.02.003 · Cited by 306
Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference
Tan, W. B., Jiang, S., & Zhang, Y. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.11.018 · Cited by 295
Immunonanoshells for targeted photothermal ablation of tumor cells
Lowery, A. R., Gobin, A. M., Day, E. S., Halas, N. J., & West, J. L. (2006) · International Journal of Nanomedicine · doi:10.2147/nano.2006.1.2.149 · Cited by 283
Li, S.-D., & Huang, L. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060039w · Cited by 282
Matrix Metalloproteinases as Therapeutic Targets in Cancer
Vihinen, P., Ala-aho, R., & Kahari, V.-M. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053765799 · Cited by 277
Banerjee, R., Tyagi, P., Li, S., & Huang, L. (2004) · International Journal of Cancer · doi:10.1002/ijc.20452 · Cited by 274
Cohen, T., Gitay-Goren, H., Sharon, R., Shibuya, M., Halaban, R., Levi, B.-Z., & Neufeld, G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.19.11322 · Cited by 269
Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis
Jiang, A., Lehti, K., Wang, X., Weiss, S. J., Keski-Oja, J., & Pei, D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241293698 · Cited by 267
In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
de Menezes, D. E. L., Pilarski, L. M., & Allen, T. M. (1998) · PubMed · Cited by 257
Koizumi, F., Kitagawa, M., Negishi, T., Onda, T., Matsumoto, S.-I., Hamaguchi, T., & Matsumura, Y. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1605 · Cited by 256
Nanoparticle–aptamer bioconjugates for cancer targeting
Farokhzad, O. C., Karp, J. M., & Langer, R. (2006) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.3.311 · Cited by 256
Epidermal growth factor receptor: a promising target in solid tumours
Laskin, J. J., & Sandler, A. B. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.10.002 · Cited by 253
Nanoparticle Imaging of Integrins on Tumor Cells
Montet, X., Montet-Abou, K., Reynolds, F., Weissleder, R., & Josephson, L. (2006) · Neoplasia · doi:10.1593/neo.05769 · Cited by 251
Molecular Recognition of Small‐Cell Lung Cancer Cells Using Aptamers
Chen, H. W., Medley, C. D., Sefah, K., Shangguan, D., Tang, Z., Meng, L., Smith, J. E., & Tan, W. (2008) · ChemMedChem · doi:10.1002/cmdc.200800030 · Cited by 250
Betancourt, T., Brown, B., & Brannon-Peppas, L. (2007) · Nanomedicine · doi:10.2217/17435889.2.2.219 · Cited by 249
Self-citationControl of tumour vascular permeability
Baban, D. F., & Seymour, L. W. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00003-9 · Cited by 237
Iinuma, H., Maruyama, K., Okinaga, K., Sasaki, K., Sekine, T., Ishida, O., Ogiwara, N., Johkura, K., & Yonemura, Y. (2002) · International Journal of Cancer · doi:10.1002/ijc.10242 · Cited by 216
Trastuzumab-modified nanoparticles: Optimisation of preparation and uptake in cancer cells
Steinhauser, I., Spänkuch, B., Strebhardt, K., & Langer, K. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2006.05.016 · Cited by 216
A folate receptor-targeted liposomal formulation for paclitaxel
Wu, J., Liu, Q., & Lee, R. J. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.02.027 · Cited by 212
αvβ3 and αvβ5 integrin antagonists inhibit angiogenesis in vitro
Nisato, R. E., Tille, J.-C., Jonczyk, A., Goodman, S. L., & Pepper, M. S. (2003) · Angiogenesis · doi:10.1023/b:agen.0000011801.98187.f2 · Cited by 207
Pun, S. H., Tack, F., Bellocq, N. C., Cheng, J., Grubbs, B. H., Jensen, G. S., Davis, M. E., Brewster, M., Janicot, M., Janssens, B., et al. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.7.918 · Cited by 201
Pan, X. Q., Zheng, X., Shi, G., Wang, H., Ratnam, M., & Lee, R. J. (2002) · Blood · doi:10.1182/blood.v100.2.594 · Cited by 200
The development and clinical use of trastuzumab (Herceptin).
Harries, M., & Smith, I. (2002) · Endocrine-related cancer · doi:10.1677/erc.0.0090075 · Cited by 196
Endocytosis of folate-protein conjugates: ultrastructural localization in kb cells
Turek, J. J., & Low, P. S. (1993) · Journal of Cell Science · doi:10.1242/jcs.106.1.423 · Cited by 196
Kremer, C., Breier, G., Risau, W., & Plate, K. H. (1997) · PubMed · Cited by 189
Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles
Pan, J., & Feng, S.-S. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.02.020 · Cited by 187
Transferrin As A Targeting Ligand for Liposomes and Anticancer Drugs
Singh, M. (1999) · Current Pharmaceutical Design · doi:10.2174/138161280506230110111312 · Cited by 181
Roles of membrane‐type matrix metalloproteinase‐1 in tumor invasion and metastasis
Sato, H., Takino, T., & Miyamori, H. (2005) · Cancer Science · doi:10.1111/j.1349-7006.2005.00039.x · Cited by 180
Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature
Backer, M. V., Gaynutdinov, T. I., Patel, V., Bandyopadhyaya, A. K., Thirumamagal, B. T. S., Tjarks, W., Barth, R. F., Claffey, K., & Backer, J. M. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0161 · Cited by 180
Vascularization of tumors: A review
Shubik, P. (1982) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf00409698 · Cited by 179
General aspects of the cellular response to low- and high-LET radiation
Pouget, J.-P., & Mather, S. J. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100484 · Cited by 173
Wu, J. H., Lu, Y., Lee, A., Pan, X., Yang, X., Zhao, X. B., & Lee, R. J. (2007) · PubMed · Cited by 172
Maruyama, K., Takahashi, N., Tagawa, T., Nagaike, K., & Iwatsuru, M. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00905-8 · Cited by 170
Flenniken, M. L., Liepold, L. O., Crowley, B. E., Willits, D. A., Young, M. J., & Douglas, T. (2005) · Chemical Communications · doi:10.1039/b413435d · Cited by 169
Leamon, C. P., Pastan, I., & Low, P. S. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)74542-6 · Cited by 166
Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes
Hatakeyama, H., Akita, H., Ishida, E., Hashimoto, K., Kobayashi, H., Aoki, T., Yasuda, J., Obata, K., Kikuchi, H., Ishida, T., et al. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.04.037 · Cited by 165
LHRH-conjugated Magnetic Iron Oxide Nanoparticles for Detection of Breast Cancer Metastases
Leuschner, C., Kumar, C. S., Hansel, W., Soboyejo, W., Zhou, J., & Hormes, J. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9199-7 · Cited by 165
Li, L., Wartchow, C. A., Danthi, S. N., Shen, Z., Dechene, N., Pease, J., Choi, H. S., Doede, T., Chu, P., Ning, S., et al. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.10.057 · Cited by 161
Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting
Tseng, C.-L., Wang, T.-W., Dong, G.-C., Yueh-Hsiu Wu, S., Young, T.-H., Shieh, M.-J., Lou, P.-J., & Lin, F.-H. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.05.006 · Cited by 160
Cheng, W. W. K., & Allen, T. M. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.11.005 · Cited by 159
VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo
Gosk, S., Moos, T., Gottstein, C., & Bendas, G. (2008) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.12.021 · Cited by 158
Applications of nanoparticles to diagnostics and therapeutics in colorectal cancer
Fortina, P. M., Kricka, L. J., Graves, D. J., Park, J. Y., Hyslop, T., Tam, F., Halas, N. J., Surrey, S., & Waldman, S. A. (2007) · Trends in biotechnology · doi:10.1016/j.tibtech.2007.02.005 · Cited by 155
Zhao, X. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.01.005 · Cited by 153
Kobayashi, T., Ishida, T., Okada, Y., Ise, S., Harashima, H., & Kiwada, H. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.08.039 · Cited by 153
Zhang, Y., & Zhang, J. (2004) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2004.09.042 · Cited by 150
Verbeek, B. S., Adriaansen-slot, S. S., Feltkamp‐Vroom, T. M., Beckers, T. L., & Rijksen, G. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00224-5 · Cited by 150
Cao, Y. (2004) · The biomedical & life sciences collection. · doi:10.1016/j.semcancer.2003.09.018 · Cited by 148
Cytotoxicity of momordin-folate conjugates in cultured human cells.
Leamon, C. P., & Low, P. S. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)73992-1 · Cited by 142
Melanoma Cell Lines Express VEGF Receptor KDR and Respond to Exogenously Added VEGF
Liu, B., Earl, H. M., Baban, D., Shoaibi, M. A., Fabra, À., Kerr, D. J., & Seymour, L. W. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2832 · Cited by 141
MT1-MMP: Universal or particular player in angiogenesis?
Genı́s, L., Gálvez, B. G., Gonzalo, P., & Arroyo, A. G. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-7891-z · Cited by 141
Kunstfeld, R., Wickenhauser, G., Michaelis, U., Teifel, M., Umek, W. H., Naujoks, K., Wolff, K. S., & Petzelbauer, P. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12057.x · Cited by 139
Biodegradable Nanoparticles for Direct or Two-Step Tumor Immunotargeting
Bossy-Nobs, L., Buchegger, F., Gurny, R., & Allémann, É. (2005) · Bioconjugate Chemistry · doi:10.1021/bc050137k · Cited by 139
Selection of large diversities of antiidiotypic antibody fragments by phage display
Goletz, S., Christensen, P. A., Kristensen, P. K., Blohm, D. H., Tomlinson, I. M., Winter, G. P., & Karsten, U. R. (2002) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.5314 · Cited by 138
Shmeeda, H., Mak, L., Tzemach, D., Astrahan, P., Tarshish, M., & Gabizon, A. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0543 · Cited by 137
Synthesis of Cetuximab-Immunoliposomes via a Cholesterol-Based Membrane Anchor for Targeting of EGFR
Pan, X., Wu, G. J., Yang, W., Barth, R. F., Tjarks, W., & Lee, R. J. (2006) · Bioconjugate Chemistry · doi:10.1021/bc060174r · Cited by 134
Surface‐Modified LPD Nanoparticles for Tumor Targeting
Li, S., & Huang, L. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1348.001 · Cited by 123
Chen, J., Wu, H., Deyan, H., & Xie, C. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.01.024 · Cited by 114
Sapra, P., Moase, E. H., Ma, J., & Allen, T. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0041 · Cited by 114
Lee, L. S., Conover, C., Shi, C., et al. (1999) · Bioconjugate Chemistry · doi:10.1021/bc990076o · Cited by 113
Ligand based dendritic systems for tumor targeting
Agarwal, A., Saraf, S., Asthana, A., Gupta, U. D., Gajbhiye, V., & Jain, N. K. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.09.024 · Cited by 112
EGFR gene amplification ‐ rearrangement in human glioblastomas
Schwechheimer, K., Huang, S., & Cavenee, W. K. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910620206 · Cited by 111
Human antibodies as next generation therapeutics
van Dijk, M. A., & van de Winkel, J. G. J. (2001) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(00)00216-7 · Cited by 107
Steitz, J., Br�ck, J., Steinbrink, K., Enk, A., Knop, J. X. F. R., & Tüting, T. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000401)86:1<15::aid-ijc3>3.0.co;2-b · Cited by 106
Microcirculation of tumors part II: The supervascularized state of irradiated regressing tumors
Rubin, P., & Casarett, G. W. (1966) · Clinical Radiology · doi:10.1016/s0009-9260(66)80052-1 · Cited by 104
Hattori, Y., & Maitani, Y. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.03.007 · Cited by 102
Chen, H., Gao, J., Lu, Y., Kou, G., Zhang, H., Fan, L., Sun, Z., Guo, Y., & Zhong, Y. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.03.010 · Cited by 97
Hattori, Y., & Maitani, Y. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700844 · Cited by 97
Dienst, A., Grunow, A., Unruh, M., Rabausch, B., Nor, J. E., Fries, J. W. U., & Gottstein, C. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji130 · Cited by 87
New developments in angiogenesis: a major mechanism for tumor growth and target for therapy.
Jones, A., & Harris, A. L. (1998) · PubMed · Cited by 83
Isolation of a Colon Tumor Specific Binding Peptide Using Phage Display Selection
Kelly, K. A., & Jones, D. A. (2003) · Neoplasia · doi:10.1016/s1476-5586(03)80046-5 · Cited by 83
MT-MMPs play pivotal roles in cancer dissemination
Yana, I., & Seiki, M. (2002) · Clinical & Experimental Metastasis · doi:10.1023/a:1015527220537 · Cited by 82
Anti‐neovascular therapy by liposomal drug targeted to membrane type‐1 matrix metalloproteinase
Kondo, M., Asai, T., Katanasaka, Y., Sadzuka, Y., Tsukada, H., Ogino, K., Taki, T., Baba, K., & Oku, N. (2003) · International Journal of Cancer · doi:10.1002/ijc.11526 · Cited by 79
Kitamura, K., Takahashi, T., Yamaguchi, T., Noguchi, A., Noguchi, A., Takashina, K., Tsurumi, H., Inagake, M., Toyokuni, T., & Hakomori, S. (1991) · PubMed · Cited by 76
Liposome targeting to tumors using vitamin and growth factor receptors
Drummond, D. C., Hong, K., Park, J. W., Benz, C. C., & Kirpgtin, D. B. (2000) · Vitamins and hormones · doi:10.1016/s0083-6729(00)60022-5 · Cited by 64
Physicochemical and biological properties of poly(ethylene glycol)-coupled immunoglobuling G
Suzuki, T., Kanbara, N., Tomono, T., Hayashi, N., & Shinohara, I. (1984) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/0167-4838(84)90268-1 · Cited by 60
Nakajima, T. E., Yasunaga, M., Kano, Y., Koizumi, F., Kato, K., Hamaguchi, T., Yamada, Y., Shirao, K., Shimada, Y., & Matsumura, Y. (2008) · International Journal of Cancer · doi:10.1002/ijc.23381 · Cited by 58
Antineoplastic drugs that interfere with iron metabolism in cancer cells
Head, J. F., Wang, F., & Elliott, R. L. (1997) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(96)00010-6 · Cited by 49
Fawaz, F., Bonini, F., Guyot, M., et al. (1993) · Pharmaceutical Research · doi:10.1023/a:1018924219540 · Cited by 41
Hartman, T., Lundqvist, H., Westlin, J., & Carlsson, J. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00476-9 · Cited by 39
Davis, D. W., Herbst, R. S., & Abbruzzese, J. L. (2007) · CRC Press eBooks · doi:10.1201/9781420004298 · Cited by 38
A Review of Antibody Therapeutics and Antibody-Related Technologies for Oncology
Scallon, B. J., Snyder, L. A., Anderson, G. M., Chen, Q., Li, Y., Weiner, L. M., & Nakada, M. T. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000199196.97845.c3 · Cited by 35
Targeting of vasculature in cancer and other angiogenic diseases
Kumar, S., & Li, C. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(00)01840-8 · Cited by 31
Cited by
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Tenchov, R., Bird, R., Curtze, A. E., & Zhou, Q. (2021) · ACS Nano · doi:10.1021/acsnano.1c04996 · Cited by 2,221
Progress and challenges towards targeted delivery of cancer therapeutics
Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-03705-y · Cited by 2,220
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Metadata
- Authors
- Byrne, J. D., Betancourt, T., & Brannon-Peppas, L.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2008-12
- Volume
- 60
- Issue
- 15
- Pages
- 1615-1626
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W1990455420
- Cited by
- 1,731
- References
- 134
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.